Guided, internet based, cognitive behavioural therapy for post-traumatic stress disorder: pragmatic, multicentre, randomised controlled non-inferiority trial (RAPID).


Journal

BMJ (Clinical research ed.)
ISSN: 1756-1833
Titre abrégé: BMJ
Pays: England
ID NLM: 8900488

Informations de publication

Date de publication:
16 06 2022
Historique:
entrez: 16 6 2022
pubmed: 17 6 2022
medline: 22 6 2022
Statut: epublish

Résumé

To determine if guided internet based cognitive behavioural therapy with a trauma focus (CBT-TF) is non-inferior to individual face-to-face CBT-TF for mild to moderate post-traumatic stress disorder (PTSD) to one traumatic event. Pragmatic, multicentre, randomised controlled non-inferiority trial (RAPID). Primary and secondary mental health settings across the UK's NHS. 196 adults with a primary diagnosis of mild to moderate PTSD were randomised in a 1:1 ratio to one of two interventions, with 82% retention at 16 weeks and 71% retention at 52 weeks. 19 participants and 10 therapists were purposively sampled and interviewed for evaluation of the process. Up to 12 face-to-face, manual based, individual CBT-TF sessions, each lasting 60-90 minutes; or guided internet based CBT-TF with an eight step online programme, with up to three hours of contact with a therapist and four brief telephone calls or email contacts between sessions. Primary outcome was the Clinician Administered PTSD Scale for DSM-5 (CAPS-5) at 16 weeks after randomisation (diagnosis of PTSD based on the criteria of the Non-inferiority was found at the primary endpoint of 16 weeks on the CAPS-5 (mean difference 1.01, one sided 95% confidence interval -∞ to 3.90, non-inferiority P=0.012). Improvements in CAPS-5 score of more than 60% in the two groups were maintained at 52 weeks, but the non-inferiority results were inconclusive in favour of face-to-face CBT-TF at this time point (3.20, -∞ to 6.00, P=0.15). Guided internet based CBT-TF was significantly (P<0.001) cheaper than face-to-face CBT-TF and seemed to be acceptable and well tolerated by participants. The main themes of the qualitative analysis were facilitators and barriers to engagement with guided internet based CBT-TF, treatment outcomes, and considerations for its future implementation. Guided internet based CBT-TF for mild to moderate PTSD to one traumatic event was non-inferior to individual face-to-face CBT-TF and should be considered a first line treatment for people with this condition. ISRCTN13697710.

Identifiants

pubmed: 35710124
doi: 10.1136/bmj-2021-069405
pmc: PMC9202033
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

e069405

Subventions

Organisme : Wellcome Trust
ID : 200796/Z/16/Z
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: All authors have completed the ICMJE uniform disclosure form at https://www.icmje.org/disclosure-of-interest/ and declare: support from the NIHR HTA programme and the Welsh Government, through Health and Care Research Wales, for the submitted work; the Spring programme was developed by and is owned by Cardiff University and, if commercialised, Cardiff University would benefit, as would authors JIB, NK, CL, and NPR; AE is an originator of cognitive therapy for PTSD and occasionally receives an honorarium for workshops on cognitive therapy for PTSD; MK receives consulting fees from eCorys Consulting and support for institutional travel from the Alan Turing Institute; no other relationships or activities that could appear to have influenced the submitted work.

Références

Arch Gen Psychiatry. 1995 Dec;52(12):1048-60
pubmed: 7492257
Int J Behav Med. 2016 Dec;23(6):776-794
pubmed: 26957109
Cogn Behav Ther. 2018 May;47(3):246-261
pubmed: 28871896
Psychol Psychother. 2021 Dec;94(4):994-1014
pubmed: 33788999
J Trauma Stress. 2008 Apr;21(2):218-22
pubmed: 18404649
Sleep. 2011 May 01;34(5):601-8
pubmed: 21532953
Trials. 2010 Mar 24;11:32
pubmed: 20334632
J Clin Psychiatry. 2000;61 Suppl 7:22-32
pubmed: 10795606
Acta Psychiatr Scand. 2019 Dec;140(6):508-521
pubmed: 31359407
Clin Psychol Rev. 2017 Mar;52:52-68
pubmed: 28013081
Health Technol Assess. 2017 Jun;21(37):1-132
pubmed: 28681717
Curr Psychiatry Rep. 2018 Oct 26;20(12):116
pubmed: 30367276
Eur J Psychotraumatol. 2020 Mar 10;11(1):1729633
pubmed: 32284821
Addiction. 1993 Jun;88(6):791-804
pubmed: 8329970
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Depress Anxiety. 2017 Jun;34(6):555-565
pubmed: 28557299
Br J Psychiatry. 2002 May;180:461-4
pubmed: 11983645
Depress Anxiety. 2018 Jun;35(6):541-550
pubmed: 29659106
Br J Psychiatry. 2012 Jan;200(1):15-21
pubmed: 22215865
Stat Med. 2006 Apr 15;25(7):1101-13
pubmed: 16345042
Cochrane Database Syst Rev. 2013 Dec 13;(12):CD003388
pubmed: 24338345
Depress Anxiety. 2013 Nov;30(11):1121-8
pubmed: 23670782
Behav Res Ther. 2003 Dec;41(12):1489-96
pubmed: 14705607
BMC Psychiatry. 2018 Mar 27;18(1):77
pubmed: 29580220
Eur J Psychotraumatol. 2020 Mar 09;11(1):1709709
pubmed: 32284816
JAMA Psychiatry. 2021 Apr 1;78(4):361-371
pubmed: 33471111
Cochrane Database Syst Rev. 2021 May 20;5:CD011710
pubmed: 34015141
Psychol Methods. 2008 Mar;13(1):1-18
pubmed: 18331150
Behav Res Ther. 2000 Apr;38(4):319-45
pubmed: 10761279
J Clin Psychol. 1991 Nov;47(6):756-61
pubmed: 1757578
JAMA. 2012 Dec 26;308(24):2594-604
pubmed: 23268518
Psychol Assess. 2018 Mar;30(3):383-395
pubmed: 28493729
Med Care. 2003 May;41(5):582-92
pubmed: 12719681
Eur J Psychotraumatol. 2015 Aug 14;6:28186
pubmed: 26290178
J Trauma Stress. 2015 Jun;28(3):191-7
pubmed: 25990825
J Trauma Stress. 2013 Oct;26(5):537-47
pubmed: 24151000
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Eval Program Plann. 1979;2(3):197-207
pubmed: 10245370
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Internet Interv. 2020 May 07;21:100326
pubmed: 32477885

Auteurs

Jonathan I Bisson (JI)

Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK bissonji@cardiff.ac.uk.

Cono Ariti (C)

Centre for Trials Research, Cardiff University, Cardiff, UK.

Katherine Cullen (K)

Swansea Centre for Health Economics, Swansea University, Swansea, UK.

Neil Kitchiner (N)

Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK.
Psychology and Psychological Therapies Directorate, Cardiff and Vale University Health Board, Cardiff, UK.

Catrin Lewis (C)

Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK.

Neil P Roberts (NP)

Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK.
Psychology and Psychological Therapies Directorate, Cardiff and Vale University Health Board, Cardiff, UK.

Natalie Simon (N)

Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK.

Kim Smallman (K)

Centre for Trials Research, Cardiff University, Cardiff, UK.

Katy Addison (K)

Centre for Trials Research, Cardiff University, Cardiff, UK.

Vicky Bell (V)

Division of Nursing, Midwifery, and Social Work, University of Manchester, Manchester, UK.

Lucy Brookes-Howell (L)

Centre for Trials Research, Cardiff University, Cardiff, UK.

Sarah Cosgrove (S)

Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK.

Anke Ehlers (A)

University of Oxford and Oxford Health NHS Foundation Trust, Oxford, UK.

Deborah Fitzsimmons (D)

Swansea Centre for Health Economics, Swansea University, Swansea, UK.

Paula Foscarini-Craggs (P)

Centre for Trials Research, Cardiff University, Cardiff, UK.

Shaun R S Harris (SRS)

Swansea Centre for Health Economics, Swansea University, Swansea, UK.

Mark Kelson (M)

Department of Mathematics, College of Engineering, Mathematics and Physical Sciences, University of Exeter, Exeter, UK.

Karina Lovell (K)

Division of Nursing, Midwifery, and Social Work, University of Manchester, Manchester, UK.

Maureen McKenna (M)

NHS Lothian, Edinburgh, UK.

Rachel McNamara (R)

Centre for Trials Research, Cardiff University, Cardiff, UK.

Claire Nollett (C)

Centre for Trials Research, Cardiff University, Cardiff, UK.

Tim Pickles (T)

Centre for Trials Research, Cardiff University, Cardiff, UK.

Rhys Williams-Thomas (R)

Centre for Trials Research, Cardiff University, Cardiff, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH